Plus Therapeutics (PSTV) appointed Michael Rosol as Chief Development Officer. Rosol will lead the company’s clinical, pre-clinical, and biomarker development activities. Rosol most recently served as Chief Medical Officer and Senior Vice President at Navidea Biopharmaceuticals. Prior to his most recent role, Rosol worked at Novartis Pharmaceuticals.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV: